SuperworthVir Biotechnology market cap VIR
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $1.8B
- Highest close in our data
- $9.8B
- Feb 2021
Vir Biotechnology is worth $1.8B at the close on Oct 23, 2026, at $10.57 a share.
That is up 115% over the last year and down 64% over five years.
Its highest close in our data was $9.8B in Feb 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.8B | $813.9M | $2B | +114% |
| 2025 | $834.8M | $597.3M | $1.7B | −19% |
| 2024 | $1B | $980.6M | $1.6B | −24% |
| 2023 | $1.4B | $1B | $4.1B | −60% |
| 2022 | $3.4B | $2.5B | $5.1B | −39% |
| 2021 | $5.5B | $3.5B | $9.8B | +61% |
| 2020 | $3.4B | $1.3B | $6.7B | +151% |
| 2019 | $1.4B | $1.3B | $1.5B | n/a |
Against its peers
Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.
| Company | Market cap |
|---|---|
| VIRVir Biotechnology | $1.8B |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| MGTXMeiraGTx | $884.6M |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| PLXProtalix BioTherapeutics | $205.5M |
| EXELExelixis | $16B |
| Peer median | $9.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Vir Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.